Renal Safety of Intravitreal Ranibizumab and the Effects of SGLT2 Inhibition in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial
Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11239-11247
DOI: 10.1111/dom.71314 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 09.09.2026. Verfasst von Toshiki Sakai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and Metabolic Medicine, Center for Preventive Medical Science, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Diabetic Retinopathy, Kidney, Macular Edema. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Aims
To evaluate whether intravitreal ranibizumab (IVR) frequency is associated with longitudinal renal markers in diabetic macular oedema (DMO) and whether the expected systemic renal and haematological effects of SGLT2 inhibition are reproduced. Materials and Methods In this post hoc sub‐analysis of the prospective COMET randomised controlled trial, 53 participants were analysed. The estimated glomerular filtration rate (eGFR), haematocrit (Hct), and urinary albumin‐to‐creatinine ratio (UACR) were assessed over 48 weeks using linear mixed‐effects models with the treatment group, week, group‐by‐week interaction, and cumulative IVR as fixed effects.
Results
Baseline eGFR was preserved (72.2 ± 18.5 mL/min/1.73 m 2 ) despite common albuminuria (median UACR 50.6 mg/gCr); mean cumulative IVR at week 48 was 7.00 ± 4.42. Cumulative IVR was not significantly associated with eGFR (−0.22 mL/min/1.73 m 2 per injection; 95% CI −0.59 to 0.15; p = 0.25), ln(UACR), or Hct. The SGLT2 inhibitor reproduced an early eGFR dip and Hct rise.
Conclusions
No statistically significant exposure‐response association was detected between cumulative IVR and renal markers within the COMET trial cohort and dosing range. Because all participants received IVR and the sample size was modest, small cumulative renal effects cannot be excluded. Trial Registration: University Hospital Medical Information Network Center (UMIN000057674); Japan Registry of Clinical Trials (jRCTs031180210, parent COMET trial)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition and Metabolic Medicine, Center for Preventive Medical Science, Chiba University, Chiba, Japan.
- Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, Kisarazu, Japan.
- Department of Internal Medicine, Minami-Boso City Tomiyama National Health Insurance Hospital, Minami-Boso, Japan.
- Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
- Department of Ophthalmology, Chiba Rosai Hospital, Chiba, Japan.
- Department of Ophthalmology and Vision Science, Chiba University Graduate School of Medicine, Chiba, Japan.
ORCID-Profile: Ryoichi Ishibashi, Masaya Koshizaka, Koutaro Yokote
Zitieren
APA
Sakai, T., Ishibashi, R., Koshizaka, M., Takatsuna, Y., Tatsumi, T., Baba, T., Sakurai, K., Maezawa, Y., & Yokote, K. (2026). Renal Safety of Intravitreal Ranibizumab and the Effects of SGLT2 Inhibition in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial. Diabetes, Obesity and Metabolism, 28(12), 11239-11247. https://doi.org/10.1111/dom.71314
Vancouver
Sakai T, Ishibashi R, Koshizaka M, Takatsuna Y, Tatsumi T, Baba T, et al. Renal Safety of Intravitreal Ranibizumab and the Effects of SGLT2 Inhibition in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial. Diabetes, Obesity and Metabolism. 2026;28(12):11239-11247. doi:10.1111/dom.71314
BibTeX
@article{Sakai2026,
author = {Sakai, Toshiki and Ishibashi, Ryoichi and Koshizaka, Masaya and Takatsuna, Yoko and Tatsumi, Tomoaki and Baba, Takayuki and Sakurai, Kenichi and Maezawa, Yoshiro and Yokote, Koutaro},
title = {Renal Safety of Intravitreal Ranibizumab and the Effects of SGLT2 Inhibition in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {12},
pages = {11239--11247},
doi = {10.1111/dom.71314}
}
EUVIMED